A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults

Start Date26 Sep 2023

Sponsor / Collaborator-

NCT04556526 / CompletedPhase 3

A Phase 3 Open-label Randomized Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women

The purpose of this study is: a) to assess adverse maternal/fetal outcomes in pregnant women randomized to receive the 2- dose Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo [Group A]) and in control women (unvaccinated pregnant women [Group B]); and b) to assess adverse neonatal/infant outcomes in neonates/infants born to women randomized to receive the 2-dose Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo [Group A]) and in neonates/infants born to control women (unvaccinated during pregnancy [Group B]).

Start Date05 Oct 2020

Sponsor / Collaborator

Janssen Vaccines & Prevention BV

[+2]

NCT04228783 / CompletedPhase 3

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety, Reactogenicity, and Consistency of a Heterologous 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN®-Filo in Adult Participants

The purpose of this study is to demonstrate that the paired 2-dose vaccine regimens from 3 consecutively manufactured lots of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 and 3 consecutively manufactured lots of Modified Vaccinia Ankara Bavarian Nordic vector encoding multiple filovirus proteins (MVA-BN-Filo) including the ebola virus mayinga glycoprotein as Dose 2, administered at a 56-day interval, induce an equivalent humoral immune response.

Start Date18 Feb 2020

Sponsor / Collaborator

Janssen Vaccines & Prevention BV

100 Clinical Results associated with MVA-BN-Filo(Bavarian Nordic, Crucell)

100 Translational Medicine associated with MVA-BN-Filo(Bavarian Nordic, Crucell)

100 Patents (Medical) associated with MVA-BN-Filo(Bavarian Nordic, Crucell)

Literatures (Medical) associated with MVA-BN-Filo(Bavarian Nordic, Crucell)

01 Feb 2024·The Lancet. Infectious diseases

Prevention and post-exposure management of occupational exposure to Ebola virus

Review

Author: Marshall, Caroline ; Moso, Michael A ; Williams, Eloise ; Lim, Chuan K ; McCarthy, James ; Williamson, Deborah A

There have been significant advances in the prevention and management of Ebola virus disease (EVD) caused by Zaire Ebola virus (ZEBOV), including the development of two effective vaccines, rVSV-ZEBOV and Ad26.ZEBOV/MVA-BN-Filo. In addition, ZEBOV monoclonal antibodies have become first-line therapy for EVD. However, the 2022-23 outbreak of Sudan Ebola virus (SUDV) in Uganda has highlighted the gap in current therapies and vaccines, whose efficacy is uncertain against non-ZEBOV species. Health-care and laboratory staff working in EVD treatment centres or Ebola virus diagnostic and research laboratories face unique risks relating to potential occupational exposure to Ebola viruses. Given the substantial morbidity and mortality associated with EVD, facilities should have strategies in place to manage occupational exposures, including consideration of post-exposure therapies. In this Review, we discuss currently available evidence for prevention and post-exposure prophylaxis of EVD, including therapies currently under evaluation for SUDV.

01 Dec 2023·Vaccine

Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda

Article

Author: Florence, Nambaziira ; Anywaine, Zacchaeus ; Ann Mwangi, Irene ; Ayoub, Kakande ; Katwere, Michael ; Ayieko, Philip ; Abu-Baker Mustapher, Ggayi ; Kaleebu, Pontiano ; Edward Connor, Nicholas ; Njie, Yusupha ; Manno, Daniela ; Watson-Jones, Deborah ; Mundia Muriuki, Moses ; Lowe, Brett ; Anzala, Omu ; Man-Lik Choi, Edward ; Kasonia, Kambale ; Greenwood, Brian ; Omosa-Manyonyi, Gloria ; Luhn, Kerstin ; Gaddah, Auguste ; Robinson, Cynthia ; Vudriko, Tobias ; Musila Mutua, Michael ; Foster, Julie ; McLean, Chelsea

BACKGROUND:

People living with HIV constitute an important part of the population in regions at risk of Ebola virus disease outbreaks. The two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen induces strong immune responses in HIV-positive (HIV+) adults but the durability of this response is unknown. It is also unclear whether this regimen can establish immune memory to enable an anamnestic response upon re-exposure to antigen.

METHODS:

This paper describes an open-label, phase 2 trial, conducted in Kenya and Uganda, of Ad26.ZEBOV booster vaccination in HIV+ participants who had previously received the Ad26.ZEBOV, MVA-BN-Filo primary regimen. HIV+ adults with well-controlled infection and on highly active antiretroviral therapy were enrolled, vaccinated with booster, and followed for 28 days. The primary objectives were to assess Ad26.ZEBOV booster safety and antibody responses against the Ebola virus glycoprotein using the Filovirus Animal Non-Clinical Group ELISA.

RESULTS:

The Ad26.ZEBOV booster was well-tolerated in HIV+ adults with mostly mild to moderate symptoms. No major safety concerns or serious adverse events were reported. Four and a half years after the primary regimen, 24/26 (92 %) participants were still classified as responders, with a pre-booster antibody geometric mean concentration (GMC) of 726 ELISA units (EU)/mL (95 %CI 447-1179). Seven days after the booster, the GMC increased 54-fold to 38,965 EU/mL (95 %CI 23532-64522). Twenty-one days after the booster, the GMC increased 176-fold to 127,959 EU/mL (95 %CI 93872-174422). The responder rate at both post-booster time points was 100 %.

CONCLUSIONS:

The Ad26.ZEBOV booster is safe and highly immunogenic in HIV+ adults with well-controlled infection. The Ad26.ZEBOV, MVA-BN-Filo regimen can generate long-term immune memory persisting for at least 4·5 years, resulting in a robust anamnestic response.

TRIAL REGISTRATION:

Pan African Clinical Trial Registry (PACTR202102747294430).

CLINICALTRIALS:

gov (NCT05064956).

01 Nov 2023·The Lancet. Global health

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone

Article

BACKGROUND:

This study assessed the safety and immunogenicity of the Ad26.ZEBOV and MVA-BN-Filo Ebola virus (EBOV) vaccine regimen in infants aged 4-11 months in Guinea and Sierra Leone.

METHODS:

In this phase 2, randomised, double-blind, active-controlled trial, we randomly assigned healthy infants (1:1 in a sentinel cohort, 5:2 for the remaining infants via an interactive web response system) to receive Ad26.ZEBOV followed by MVA-BN-Filo (Ebola vaccine group) or two doses of meningococcal quadrivalent conjugate vaccine (control group) administered 56 days apart. Infants were recruited at two sites in west Africa: Conakry, Guinea, and Kambia, Sierra Leone. All infants received the meningococcal vaccine 8 months after being randomly assigned. The primary objective was safety. The secondary objective was immunogenicity, measured as EBOV glycoprotein-binding antibody concentration 21 days post-dose 2, using the Filovirus Animal Non-Clinical Group ELISA. This study is registered with ClinicalTrials.gov (NCT03929757) and the Pan African Clinical Trials Registry (PACTR201905827924069).

FINDINGS:

From Aug 20 to Nov 29, 2019, 142 infants were screened and 108 were randomly assigned (Ebola vaccine n=75; control n=33). The most common solicited local adverse event was injection-site pain (Ebola vaccine 15 [20%] of 75; control four [12%] of 33). The most common solicited systemic adverse events with the Ebola vaccine were irritability (26 [35%] of 75), decreased appetite (18 [24%] of 75), pyrexia (16 [21%] of 75), and decreased activity (15 [20%] of 75). In the control group, ten (30%) of 33 had irritability, seven (21%) of 33 had decreased appetite, three (9%) of 33 had pyrexia, and five (15%) of 33 had decreased activity. The frequency of unsolicited adverse events was 83% (62 of 75 infants) in the Ebola vaccine group and 85% (28 of 33 infants) in the control group. No serious adverse events were vaccine-related. In the Ebola vaccine group, EBOV glycoprotein-binding antibody geometric mean concentrations (GMCs) at 21 days post-dose 2 were 27 700 ELISA units (EU)/mL (95% CI 20 477-37 470) in infants aged 4-8 months and 20 481 EU/mL (15 325-27 372) in infants aged 9-11 months. The responder rate was 100% (74 of 74 responded). In the control group, GMCs for both age groups were less than the lower limit of quantification and the responder rate was 3% (one of 33 responded).

INTERPRETATION:

Ad26.ZEBOV and MVA-BN-Filo was well tolerated and induced strong humoral responses in infants younger than 1 year. There were no safety concerns related to vaccination.

FUNDING:

Janssen Vaccines & Prevention and Innovative Medicines Initiative 2 Joint Undertaking.

TRANSLATION:

For the French translation of the abstract see Supplementary Materials section.

News (Medical) associated with MVA-BN-Filo(Bavarian Nordic, Crucell)

28 Jun 2024

·www.globenewswire.com

Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa

Bavarian Nordic is committed to support global efforts to address the mpox situation in Africa through a donation of 15,000 doses of mpox vaccineEmergency Use Authorization for the MVA-BN vaccine has been issued in the DR Congo COPENHAGEN, Denmark, June 28, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an extended commitment to help fight the current mpox outbreak in Africa. The Company’s MVA-BN vaccine, the only FDA and EMA-approved mpox vaccine, which served as an important tool during the 2022-2023 mpox outbreak, could soon also become available in the DR Congo (DRC) and other countries in Africa. Mpox is on the rise in African countries with increasing incidence of the more severe clade I. So far in 2024, more than 9,000 mpox cases and over 400 deaths have been reported across seven African countries of which the vast majority (96%) having occurred in the DRC1. Earlier this week, the regulatory authorities in the DRC, ACOREP (Autorité Congolaise de Réglementation Pharmaceutique), issued an Emergency Use Authorization allowing for the use of the MVA-BN vaccine for individuals at risk of mpox. Locally, in the DRC, clinical studies are also planned to support a full regulatory approval of the MVA-BN vaccine, as recently announced by Bavarian Nordic. To further strengthen the response in the DRC and throughout the African region, Bavarian Nordic will collaborate with global health partners, including WHO, UNICEF and Gavi. Bavarian Nordic applauds Gavi’s Board decision to approve a new Vaccine Investment Strategy which includes the establishment of a global mpox vaccine stockpile. In the near term, Bavarian Nordic is committed to work in partnership with Gavi, WHO and UNICEF to coordinate dose donations in response to the ongoing outbreak in the DRC and other African countries. To support these efforts, Bavarian Nordic has committed to donating 15,000 doses of its MVA-BN mpox vaccine to the African response. “The spread of mpox in the Democratic Republic of the Congo and elsewhere is highly concerning and could pose a global threat if it is not urgently contained,” said Dr Sania Nishtar, CEO of Gavi, the Vaccine Alliance. “Gavi and its partners welcome Bavarian Nordic’s resolve to help fight this outbreak and its contribution in doses. Our Alliance welcomes the availability of new vaccines for countries and is committed to working with Bavarian Nordic and the relevant authorities to facilitate their arrival and timely administration in line with country plans.” “Mpox has been a public health threat in several African countries for more than 50 years and is now spreading across the continent with higher incidence and severity. Global partners are uniting to build a stronger public health response throughout the affected region. and we are proud to contribute through a donation of our mpox vaccine,” said Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic. About mpox in the DRC and other African countriesAfrica is currently tackling one of the largest and deadliest known mpox outbreak to date. Over 8,700 mpox cases and 408 deaths have been reported in the DRC this year alone, with children accounting for the majority of infections and deaths. Cases have also been confirmed in the Republic of Congo, Cameroon, Central African Republic, Ghana, Liberia and South Africa. Mpox was first identified in the DR Congo in 1970. In most cases, mpox symptoms - typically fever and headache, followed by painful lesions - resolve within a few weeks. However, for some, mpox can lead to medical complications, such as bronchopneumonia, sepsis, encephalitis, loss of vision, or death. The mpox virus strain behind the current outbreak, known as clade I, is estimated to be fatal in up to 10% of cases. About the smallpox/mpox vaccineMVA-BN or Modified Vaccinia Ankara-Bavarian Nordic is a non-replicating smallpox vaccine and the only mpox vaccine approved in the U.S. and Switzerland (marketed as JYNNEOS®), Canada (marketed as IMVAMUNE®), and the EU/EEA and United Kingdom (marketed as IMVANEX®). Originally developed in collaboration with the U.S. government to ensure the supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines, MVA-BN has been indicated for use in the general adult population (18 years and older) in individuals considered at risk for smallpox or mpox. During the 2022-2023 mpox outbreak, the vaccine was granted an Emergency Use Authorization by the U.S. FDA for both pre- and post-exposure use in adolescents. Bavarian Nordic has been a long-term supplier of the vaccine to the U.S. and Canada as well as several other countries as part of their national biological preparedness. During the 2022-2023 mpox outbreak, Bavarian Nordic has furthermore supported governments and supranational organizations by expanding access to the vaccine to more than 70 countries worldwide. About Bavarian NordicBavarian Nordic is a fully integrated vaccine company with a mission to protect and save lives through innovative vaccines. We are a global leader in smallpox and mpox vaccines, supplied to governments to enhance public health preparedness and have a strong portfolio of vaccines for travelers and endemic diseases. For more information visit www.bavarian-nordic.com. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance, and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. ContactsEurope: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600 1 https://africacdc.org/download/africa-cdc-weekly-event-based-surveillance-report-june-2024/ Attachment 2024-06-28-en

Drug ApprovalVaccineAccelerated Approval

14 Dec 2022

·www.reuters.com

J&J and Merck Ebola vaccines produce lasting antibodies in children and adults -studies

Dec 14 (Reuters) - Ebola vaccines developed by Johnson & Johnson and Merck & Co (MRK.N) produced virus-fighting antibodies and appear to be safe in children and adults, according to data from two studies published on Wednesday. Both companies' vaccines produced antibodies 14 days after the first of two shots and were detectable at varying levels in both children and adults for one year, data from the studies conducted in Western Africa showed. The vaccines are designed to target the Zaire strain of the virus, not the Sudan strain of Ebola that recently caused an outbreak and at least 56 deaths in Uganda. One regimen tested a dose of J&J's vaccine, followed by a booster shot of a vaccine from Danish drugmaker Bavarian Nordic (BAVA.CO) , while another tested two doses of Merck's vaccine with eight weeks in between. A third option followed the first Merck dose with a placebo. "I think the study shows that both the vaccines elicit good antibody responses," said Dr. H. Clifford Lane, one of the researchers and a clinical director at the U.S. National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH). Only Merck's shot can potentially be given as a single dose while J&J's vaccine may need to continue as a two-dose regimen, Lane added. The NIH researchers noted that they were unable to assess the actual level of protection against the disease from the vaccines as no participants contracted Ebola during the trial, which began enrollment in 2017. But they said the vaccines were found to be safe for children and adults. "Long-term follow up of the participants in this trial is taking place to determine if and when booster doses might be needed," said Brian Greenwood, a study co-author from the London School of Hygiene & Tropical Medicine. A total of 1,400 adults and 1,401 children aged 1 to 17 years old participated in the trials conducted in collaboration with Liberia Ministry of Health and with the University Clinical Research Center and the Center for Vaccine Development-Mali. The results were published in The New England Journal of Medicine. Merck's vaccine Ervebo was approved by the European regulator and prequalified by the World Health Organization in 2019. J&J's Zabdeno got European and WHO clearances in 2020 and 2021, respectively. Bavarian Nordic's Mvabea, used in the J&J regimen, also received European approval in 2020 and WHO prequalification in 2021. Our Standards: The Thomson Reuters Trust Principles.

Drug ApprovalVaccineClinical ResultPhase 3

14 Dec 2022

·www.sciencedaily.com

Ebola vaccine regimens safe, immunogenic in adults and children

Two randomized, placebo-controlled trials evaluating three Ebola vaccine administration strategies in adults and children found that all the regimens were safe in both age groups, according to new results. Antibodies were produced in response to the vaccine regimens beginning at 14 days after the first vaccination and continued to be detectable at varying levels -- depending on the vaccine and regimen used -- in both children and adults for one year. The study enrolled volunteers at sites in Guinea, Liberia, Sierra Leone and Mali to identify optimal vaccination strategies to curtail outbreaks of Ebola virus disease. Two randomized, placebo-controlled trials evaluating three Ebola vaccine administration strategies in adults and children found that all the regimens were safe in both age groups, according to results published today in the New England Journal of Medicine. Antibodies were produced in response to the vaccine regimens beginning at 14 days after the first vaccination and continued to be detectable at varying levels -- depending on the vaccine and regimen used -- in both children and adults for one year. The study enrolled volunteers at sites in Guinea, Liberia, Sierra Leone and Mali to identify optimal vaccination strategies to curtail outbreaks of Ebola virus disease. The trials were conducted under the Partnership for Research on Ebola Vaccination (PREVAC) international consortium. PREVAC's partner organizations include the U.S. National Institutes of Health (NIH), the French National Institute of Health and Medical Research and the London School of Hygiene & Tropical Medicine. The National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, sponsored the trial in Liberia and Mali. In Liberia, the study was done in collaboration with the Liberia Ministry of Health through the Partnership for Research on Ebola Virus in Liberia program. In Mali, it was conducted in collaboration with the University Clinical Research Center and the Center for Vaccine Development-Mali. The trials began enrollment in 2017, were conducted simultaneously and shared a placebo arm. A total of 1,400 adults and 1,401 children aged 1 year to 17 years old were randomized to receive two injections of either placebo or Ebola vaccine in one of three regimens. The Ebola vaccine regimens were Ad26.ZEBOV (supplied by Johnson & Johnson) followed eight weeks later with a booster dose of MVA-BN-Filo vaccine (supplied by manufacturer Bavarian Nordic); two doses of rVSVΔG-ZEBOV-GP (manufactured by Merck Sharp & Dohme Corp) separated by eight weeks; or one dose of the Merck vaccine followed eight weeks later by a placebo injection. Antibody responses were observed by day 14 after the first injection of either Ad26.ZEBOV or rVSVΔG-ZEBOV-GP vaccine. The researchers say this finding is notable because vaccines against Ebola virus disease are typically administered during an outbreak and so information about how rapidly a vaccine produces an antibody effect is of potential use in efforts to protect at-risk populations. However, it is not currently known what level of antibody response reliably correlates with vaccine-induced protection against Ebola virus infection or disease. As no participants contracted Ebola virus disease during the trial, the investigators were not able to assess protection from disease. The researchers cite several strengths of the trials, including outstanding retention of volunteers throughout the course of trial, achieved with continuing community engagement and ongoing trust-building efforts.

VaccineClinical ResultClinical Study

100 Deals associated with MVA-BN-Filo(Bavarian Nordic, Crucell)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BX	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hemorrhagic Fever, Ebola	EU	Janssen-Cilag International NV	01 Jul 2020
Hemorrhagic Fever, Ebola	IS	Janssen-Cilag International NV	01 Jul 2020
Hemorrhagic Fever, Ebola	LI	Janssen-Cilag International NV	01 Jul 2020
Hemorrhagic Fever, Ebola	NO	Janssen-Cilag International NV	01 Jul 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 2	BF	Janssen Vaccines & Prevention BV	06 Nov 2015
HIV Infections	Phase 2	CI	Janssen Vaccines & Prevention BV	06 Nov 2015
HIV Infections	Phase 2	KE	Janssen Vaccines & Prevention BV	06 Nov 2015
HIV Infections	Phase 2	UG	Janssen Vaccines & Prevention BV	06 Nov 2015
Marburg Virus Disease	Phase 1	US	National Institute of Allergy & Infectious Diseases	24 Mar 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02661464 (CTgov)	Phase 3	Hemorrhagic Fever, Ebola	677	MVA-BN-Filo+Ad26.ZEBOV (Cohort 1: Ad26.ZEBOV + MVA-BN-Filo)	vscqpoakog(xdgjkiwxma) = jvpvzlgjro gxhfqvomlk (wakqybqpbq, pzktomudqy - gglkomylwb) View more	-	02 Jan 2024
				placebo+MVA-BN-Filo+Ad26.ZEBOV (Cohort 1: Placebo)	vscqpoakog(xdgjkiwxma) = bdygibjfyd gxhfqvomlk (wakqybqpbq, odtufjlssa - vtsflboual) View more
NCT03929757 (CTgov)	Phase 2	Hemorrhagic Fever, Ebola	108	MVA-BN-Filo+Ad26.ZEBOV (Main Study: Ad26.ZEBOV + MVA-BN-Filo + MenACWY)	aglzrsnimg(dcbrjmdbyy) = aqkuxjuqon grdtvvdawx (anjzyiyqvt, cedtjtxbrl - dtcuprmxzj) View more	-	22 Jun 2023
				MenACWY vaccine (Main Study: MenACWY (Control Arm))	aglzrsnimg(dcbrjmdbyy) = fbuhhkfvso grdtvvdawx (anjzyiyqvt, kobuywzkky - hdwwuxtxrm) View more
NCT04228783 (CTgov)	Phase 3	Hemorrhagic Fever, Ebola	974	MVA-BN-Filo+Ad26.ZEBOV (Ad26.ZEBOV(Lot A), MVA-BN-Filo (Lot 1) (Group 1))	pxzgnkjoit(hzwskowyoi) = hvjcmghztd oafudrpnvt (rttluitgax, xkjgjhorty - nlckqrpmwz) View more	-	17 May 2023
				MVA-BN-Filo+Ad26.ZEBOV (Ad26.ZEBOV(Lot B), MVA-BN-Filo (Lot 2) (Group 2))	pxzgnkjoit(hzwskowyoi) = qwemqciiyz oafudrpnvt (rttluitgax, yjnnsbemkc - aramkfkhjo) View more
NCT02509494 (EBOVAC-Salone, CTgov)	Phase 3	Hemorrhagic Fever, Ebola	1,023	MVA-BN-Filo (Ad26.ZEBOV)+Ad26.ZEBOV (Stage 1 (>=18 Years): Ad26.ZEBOV, MVA-BN-Filo (Ad26.ZEBOV))	agrrirtgmw(clzqrotjrt) = zrcajjcxcg zkxpjffwtw (tbmtxohger, zvcgggwzsn - cqmziluzvf) View more	-	18 Jul 2022
				MVA-BN-Filo+Ad26.ZEBOV (Stage 2 (>=18 Years): Ad26.ZEBOV, MVA-BN-Filo)	agrrirtgmw(clzqrotjrt) = fofueogjne zkxpjffwtw (tbmtxohger, hhpvtwpvup - ffrxztqvgj) View more
NCT03583606 (CTgov)	Phase 1	Hemorrhagic Fever, Ebola	61	Placebo+ChAd3-EBO-Z (ChAd3-EBO-Z + Placebo)	bgdpmbtmyk(dcivccmuln) = xsicqoxtme cnthlsuici (acejfeoslv, dofzwyxdlh - iqljmrlqzi) View more	-	02 Jun 2021
				ChAd3-EBO-Z (ChAd3-EBO-Z + ChAd3-EBO-Z)	bgdpmbtmyk(dcivccmuln) = befxyzckyp cnthlsuici (acejfeoslv, pkjogpsjck - rggwtvlela) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

MVA-BN-Filo(Bavarian Nordic, Crucell)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation